Results of adjuvant chemotherapy for invasive urothelial cancer with lymph-node metastasis.
From 1980 to 1991, 59 patients with advanced urothelial cancer (pathological stage, > pT3) underwent radical operations. Of these 59 patients, 33 had nodal involvement. This study focused on those 33 patients with nodal involvement. The primary site was the urinary bladder in 20 patients and the upper urinary tract (renal pelvis and/or ureter) in 13. In all, 13 patients underwent adjuvant chemotherapy with an M-VAC or M-VEC [methotrexate (M), vinblastine, doxorubicin (ADM) or epirubicin, and cisplatin (CDDP)] regimen, and another 8 patients were treated with other insufficient chemotherapies [CDDP + ADM or CDDP + ADM + etoposide (VP-16)]. A group of 12 patients did not receive any additional treatment. Most of the patients in the M-VAC and M-VEC groups received more than 2 cycles of the regimen (median, 3.2 cycles; range, 1-9 cycles). The overall 5-year survival rate of the M-VAC and M-VEC group was 31%, whereas the rate was 0 for the other insufficient-chemotherapy groups and the no-chemotherapy group. Of the 13 patients in the M-VAC group, 4 (31%) patients were alive without disease progression and 9 (69%) were dead due to progressive disease. In the other groups, only 1 patient was alive without progression. Our results suggest that adjuvant M-VAC or M-VEC chemotherapy may extend the median survival of patients with advanced urothelial cancer, but it failed to reduce the rate of cancer death.
Kobayashi
H
H
Department of Urology, Japanese Red Cross Nagoya Second Hospital.
Obata
K
K
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary / Q000601:surgery; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D007682:Kidney Pelvis; D008137:Longitudinal Studies; D008207:Lymphatic Metastasis; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D015996:Survival Rate; D014516:Ureteral Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D014571:Urologic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects
D015251:Epirubicin; D014747:Vinblastine; D005047:Etoposide; D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate